Desferrioxamine and ascorbic acid supplement in E-B thalassaemia

A K Dutta et al. J Assoc Physicians India. 1988 Jul.

. 1988 Jul;36(7):463-4.

No abstract available

Similar articles

Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
Hathirat P, Isarangkura P, Areekul S, Pleehachinda R, Tuntawiroon M. Hathirat P, et al. Birth Defects Orig Artic Ser. 1988;23(5B):129-33. Birth Defects Orig Artic Ser. 1988. PMID: 3390535 No abstract available.
Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
Nienhuis AW, Delea C, Aamodt R, Bartter F, Anderson WF. Nienhuis AW, et al. Birth Defects Orig Artic Ser. 1976;12(8):177-85. Birth Defects Orig Artic Ser. 1976. PMID: 795481 Review. No abstract available.
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E. Cartei G, et al. Minerva Med. 1978 Mar 17;69(13):811-21. Minerva Med. 1978. PMID: 643223 Italian. No abstract available.
Long-term desferrioxamine therapy in thalassemia.
Modell CB, Beck J. Modell CB, et al. Ann N Y Acad Sci. 1974;232(0):201-10. doi: 10.1111/j.1749-6632.1974.tb20586.x. Ann N Y Acad Sci. 1974. PMID: 4528634 No abstract available.
Clinical management of beta-thalassemia.
Graziano J, Piomelli S. Graziano J, et al. Tex Rep Biol Med. 1980-1981;40:355-64. Tex Rep Biol Med. 1980. PMID: 7034276 Review. No abstract available.